Kimberly-Clark Corp. will mark the 50th anniversary of its Everett paper mill, which makes tissue products and paper towels, with a celebration for employees today. During this week in 1954, Scott Paper Co.’s new mill on the Everett waterfront began full production after a year of construction. While the Scott brand is still alive, the company itself merged with Kimberly-Clark in 1995. The adjacent pulp mill dates back to the late 1920s.
Sonus Pharmaceuticals Inc. lost $2.6 million during the fourth quarter of 2003, compared with a $2.4 million loss for the same period of 2002, the Bothell company reported Tuesday. The latest net loss, which equaled 15 cents a share, beat most analysts’ forecasts of a loss of 22 cents a share. During 2003 as a whole, Sonus loss $10.5 million, down from $11.6 million in 2002. Sonus said it will advance its lead anti-cancer drug candidate, Tocosol paclitaxel, through advanced clinical trials this year, with the hope of applying for federal approval in late 2005 or early 2006.
Honeywell will supply navigation systems and other electronics for the Boeing Co.’s new 7E7. Honeywell spokesman Ron Crotty said it’s too early to say whether any of the work will be done in Everett, where Boeing will assemble the new jet. The Phoenix-based company has about 1,000 Puget Sound-area employees. On the 7E7, Honeywell will provide a navigation package that includes systems to measure air speed and altitude, and determine the aircraft’s location.
Bothell-based Epoch Biosciences has signed a license agreement with California-based Celera Diagnostics to incorporate Epoch’s patented DNA testing tools into products that detect infectious diseases. Epoch will receive fees and royalties from the sale of products that use its technology. Specific terms of the deal were not disclosed. William Gerber, Epoch’s chief executive officer, said the agreement represents the company’s first business agreement in the field of human diagnostics. Epoch’s stock rose by 18 cents, or 7 percent, on Tuesday to close at $2.68 a share.
Seattle Genetics Inc. said the underwriters of last week’s sale of stock in the Bothell company exercised their option to buy more than 1 million additional shares. That brings gross proceeds from the stock offering, which is now complete, to more than $66 million. At Tuesday’s close of the markets, Seattle Genetics’ stock was $8.89 a share, up 40 cents.
Herald staff
Talk to us
> Give us your news tips.
> Send us a letter to the editor.
> More Herald contact information.
